Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/13/2023 | $30.00 → $28.00 | Neutral → Underweight | JP Morgan | |
| 1/17/2023 | $30.00 → $25.00 | Overweight → Underweight | Barclays | |
| 1/13/2023 | $25.00 | Overweight → Underweight | Barclays | |
| 12/14/2022 | $66.00 → $38.00 | Buy → Neutral | Mizuho | |
| 11/7/2022 | $55.00 → $27.00 | Outperform → In-line | Evercore ISI | |
| 10/18/2022 | $85.00 → $53.00 | Overweight → Neutral | JP Morgan | |
| 9/14/2022 | Buy → Neutral | Guggenheim | ||
| 9/7/2022 | $68.00 | Neutral | UBS |
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
https://www.marijuanamoment.net/gop-congressional-committee-approves-bill-to-block-marijuana-rescheduling-while-rejecting-state-cannabis-protections-amendment/
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows: USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied. CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until
BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on FSD Pharma, Inc. (NASDAQ:HUGE)(CSE:HUGE), an innovative biopharmaceutical firm with one product slated for commercialization in 1Q24 and a unique treatment for MS preparing a Phase II clinical trial for 2H24 The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit https://bit.ly/3Rer5Av.FSD Pharma is a biopharmaceutical company building a portfolio of innovative
TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that the FSD Pharma Securityholders (defined below) have approved the previously-announced plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") pursuant to which common shares in the capital of Celly Nutrition Corp. ("Celly Nu"), will be distributed to the holders of class A multiple voting shares ("Class A Shares"), class B subordinate voting shares ("Class B Shares"), and holders of warra
TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement (the "Arrangement") is November 29, 2023 (the "Distribution Date"). Subject to the satisfaction of all applicable closing conditions of the Arrangement, common shares in the capital of Celly Nutrition Corp. ("Celly Nu Shares") will be distributed to FSD Pharma Securityholders (as defined below) of record as of No
JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00
TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.Changes in ManagementEffective August 30, 2024, Donal Carroll will assume the role of Chief Financial Officer and Nathan Coyle will assume the role of Controller. In addition, the Company has appointed Jason Sawyer as the Head of Finance and Mergers and Acquisitions for the Company.Option CancellationEffective today, the Company has cancelled an aggregate of 32,690 o
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption.On August 9, 2024, Celly Nutrition which is backed by a world-class pharmaceutical research & development team at FSD Pharma, operated by CEO John Duffy, formerly of Coca-Cola, and co-chaired by Gerry David the former CEO of Celsius Holdings (CELH) proudly announces the imminent launch of its revolutionary, great tasting and scientifically bac
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.Corporate UpdateFSD Pharma has retained the services of Totaligent, Inc. ("Totaligent") who will play a key role in assisting the Company to enhance its market awareness and foster productive, continuing dialogues with shareholders and other market participants. Totalaligent has over 25 years of experience in market awareness campaigns and has assembled a database of 32 million active investors and reaches its in
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K/A - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
TORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the appointment of Dr. Sanjiv Chopra to its board of directors. Dr. Chopra will be replacing Nitin Kaushal, who has resigned from his position on the board. FSD Pharma thanks Mr. Kaushal for his contribution and wishes him well on his future endeavours.Dr. Sanjiv ChopraDr. Sanjiv Chopra, MD, is Professor of Medicine and served as Faculty Dean for Continuing Medical Education at Harvard Medical School for 12 years. He serves as a Marshall W
TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that it has provided certain additional disclosure, by way of a Supplement dated November 15, 2023 (the "Supplement") to its Management Information Circular dated October 20, 2023 (the "Circular"), relating to certain restrictions on resale that will apply to the Celly Nu Shares that will be distributed to the FSD Pharma Securityholders. Capitalized terms not defined in this news release have the meanings assigned in the Circular.FSD Phar